DK0969873T3 - Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf - Google Patents

Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf

Info

Publication number
DK0969873T3
DK0969873T3 DK98913748T DK98913748T DK0969873T3 DK 0969873 T3 DK0969873 T3 DK 0969873T3 DK 98913748 T DK98913748 T DK 98913748T DK 98913748 T DK98913748 T DK 98913748T DK 0969873 T3 DK0969873 T3 DK 0969873T3
Authority
DK
Denmark
Prior art keywords
carbohydrate
multiple carbohydrate
vaccine
glycopeptide antigens
subject
Prior art date
Application number
DK98913748T
Other languages
Danish (da)
English (en)
Inventor
Claude Leclerc
Sylvie Bay
Daniele Cantacuzene
Richard Lo-Man
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK0969873T3 publication Critical patent/DK0969873T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Carbon And Carbon Compounds (AREA)
DK98913748T 1997-03-27 1998-03-27 Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf DK0969873T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4172697P 1997-03-27 1997-03-27

Publications (1)

Publication Number Publication Date
DK0969873T3 true DK0969873T3 (da) 2006-10-09

Family

ID=21918009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98913748T DK0969873T3 (da) 1997-03-27 1998-03-27 Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf

Country Status (10)

Country Link
US (1) US7696326B2 (fr)
EP (1) EP0969873B1 (fr)
AT (1) ATE328611T1 (fr)
AU (1) AU6832398A (fr)
CA (1) CA2285018C (fr)
DE (1) DE69834808T2 (fr)
DK (1) DK0969873T3 (fr)
ES (1) ES2265162T3 (fr)
PT (1) PT969873E (fr)
WO (1) WO1998043677A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO2000047229A2 (fr) * 1999-02-11 2000-08-17 Genzyme Corporation Concatomeres de peptide antigene
EP1417965A1 (fr) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Molécules capables de se lier à des lectines de type-C, leur identification et usages
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
EP2230249A3 (fr) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigène/anticorps ou ligand/récepteur glycosyles avec un échangeur de spécificité
CA2537900A1 (fr) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Vaccins multiplex
EP1793863B1 (fr) * 2004-10-01 2017-04-12 Midatech Ltd. Nanoparticules contenant un antigene et un adjuvant activant les cellules t auxiliaires
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2010002478A2 (fr) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide et son utilisation
WO2007079448A2 (fr) 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Vaccin glucidique à trois composants
ATE509027T1 (de) 2006-01-13 2011-05-15 Pasteur Institut Enzymatische synthese von grossen mengen von mucin glyconjugaten und deren immunogenische anwendungen
US8420067B2 (en) 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
WO2008017122A1 (fr) 2006-08-11 2008-02-14 Starpharma Pty Ltd Agent de contraste dendrimère de polylysine
AU2010232512B2 (en) 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof
EP2500033A1 (fr) * 2011-03-17 2012-09-19 Institut Pasteur Procédé pour la préparation de plusieurs conjugués de carbohydrate de glycopeptide d'antigène
TR201808684T4 (tr) * 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Lineer olmayan sakarit konjügatları.
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
KR20180086277A (ko) * 2015-12-14 2018-07-30 수 한 폴리펩티드 화합물, 그리고 이의 제조 방법 및 적용
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386026A (en) 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
EP0532525B1 (fr) * 1990-05-18 1995-08-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Nouveaux conjugues de proteines et de polycations
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
WO1993022343A1 (fr) 1992-05-01 1993-11-11 The Rockfeller University Systeme antigenique a plusieurs peptides possedant des proprietes d'adjuvant, vaccins prepares a partir dudit systeme

Also Published As

Publication number Publication date
DE69834808T2 (de) 2007-06-06
PT969873E (pt) 2006-09-29
CA2285018C (fr) 2011-01-04
EP0969873B1 (fr) 2006-06-07
US20070098730A1 (en) 2007-05-03
EP0969873A1 (fr) 2000-01-12
ES2265162T3 (es) 2007-02-01
ATE328611T1 (de) 2006-06-15
US7696326B2 (en) 2010-04-13
AU6832398A (en) 1998-10-22
WO1998043677A1 (fr) 1998-10-08
CA2285018A1 (fr) 1998-10-08
DE69834808D1 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
EP0837927A4 (fr) Anticorps monoclonaux simiens diriges specifiquement contre le b7.1 et/ou b7.2 humains, leurs formes adaptees aux primates, et compositions pharmaceutiques
BR9809656A (pt) Composição imunopotencializante
FI972945L (fi) Antigeenien antamiseen soveltuvia koostumuksia
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
EP1378525A3 (fr) Anticorps humanisés qui se lient à l'antigène relié par l'anticorp NR-LU-13 et leur utilisation dans des méthodes de ciblage
CA2025597A1 (fr) Vaccin contre la maladie de lyme
IL143797A0 (en) Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4
WO1998057994A3 (fr) Anticorps opsoniques, monoclonaux protecteurs, et chimeres specifiques a l'acide lipoteichoique des bacteries gram positif
CA2290485A1 (fr) Procede de production de proteines non immunogenes
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
WO1996029605A3 (fr) Composes et methodes de depistage de l'infection par trypanosoma cruzi
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
EP0866133A3 (fr) Un vaccin de la groupe B de Streptococcus
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
FI962844A7 (fi) T-soluantigeenireseptorin V-alueen proteiineja ja menetelmiä niiden va lmistamiseksi
IS4922A (is) Fjölpeptíð sem geta myndað formgerðir mótefnisvakabindinga með sérvirkni fyrir resus D mótefnisvaka, DNA-ið sem táknar þau og aðferðin til að búa þautil og notkun
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
EP1003494A4 (fr) (d)-METHADONE, ANALGESIQUE NON OPIOIDE
SE9401460D0 (sv) Antigen/antibody specificity exhanger
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
ATE444081T1 (de) Proteine-abgabe durch polare epithelzellen schichte
ATE207935T1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid